Shares of Argenx SE (ARGX) surged 5.17% in pre-market trading following the release of its second-quarter financial results, which significantly exceeded analyst expectations.

The biotech company reported earnings of $7.32 per share, easily surpassing the consensus estimate of $6.24. Quarterly sales reached $1.542 billion, also topping the projected $1.442 billion. These figures represent a dramatic increase from the same period last year, with earnings nearly doubling from $3.74 per share and revenue soaring 59.43%.

The robust performance underscores the growing commercial momentum for Argenx's key products. The strong beat on both top and bottom lines has fueled bullish sentiment among investors, driving the stock higher in the pre-market session.